A staggering prediction suggests that by 2035, 24 million Americans could be using GLP-1 drugs like Ozempic, leading to a massive reduction in calorie intake—equivalent to 36 million fewer Big Macs consumed daily. This shift could spell disaster for the fast food industry, with companies like McDonald's facing potential revenue losses in the billions. As obesity rates rise, the correlation between the performance of major food stocks and public health becomes increasingly apparent.
